<DOC>
	<DOCNO>NCT02541149</DOCNO>
	<brief_summary>This study aim investigate clinical utility Annexin A2 serum level novel diagnostic marker hepatocellular carcinoma ( HCC ) correlate level alpha fetoprotein current marker ofhepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Annexin A2 Novel Diagnostic Marker Hepatocellular Carcinoma</brief_title>
	<detailed_description>This study carry HCC clinic , Ain Shams University Hospitals , Cairo ; Egypt include : Group 1 : Fifty patient early stage hepatocellular carcinoma ( BCLC stage A ) ; Group 2 : Twenty five patient chronic liver disease diagnose base clinical , laboratory , ultrasonographic investigation ; Control Group : Fifteen healthy , age sex-matched subject seronegative hepatitis viral marker .All group subject thorough history taking , full clinical examination , laboratory investigation include viral hepatitis marker : HBsAg HCV antibody use ELISA technique HCV RNA use real time PCR HCV antibody positive patient , AFP electrochemiluminescence Annexin A2 estimation use ELISA technique .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Inclusion criterion HCC case : 1 . Confirmed diagnosis HCC accord European association study liver diseases [ 13 ] . 2 . Early stage HCC ( Stage A ) , use Barcelona Clinic Liver Cancer ( BCLC ) stag system , ( single 3 nodule &lt; 3cm PS 0 ) For participant : . Informed consent participant enrollment study . For HCC patient : 1Imtermediate advanced stage HCC define BCLC 2 . Major vascular tumor invasion metastasis confirm radiological imaging study . 3 . Patients suspect solid malignancy metastatic liver tumor , 4 . Other type chronic liver disease ( CLD ) autoimmune hepatitis primary biliary cirrhosis . For participant : Refusal participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>